Key result
Sarcopenic obesity, defined by the VAT:FFMI ratio, was significantly associated with an increased risk of metabolic syndrome (adjusted OR 4.06) in Northern Italian adults.
Why the study?
Is sarcopenic obesity associated with an increased risk of metabolic syndrome in Northern Italian adults?
Cross-Sectional (n=3,441)
Is sarcopenic obesity associated with an increased risk of metabolic syndrome in Northern Italian adults?
Sarcopenic obesity, defined by either VAT:FFMI or FMI:FFMI, is a strong predictor of cardiometabolic risk and metabolic syndrome in adults.
Sarcopenic obesity may flag higher metabolic syndrome risk; leaves open whether VAT:FFMI improves prediction or warrants intervention.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Lara et al. (2016) conducted a cross-sectional in Sarcopenic obesity and metabolic syndrome (n=3,441). Sarcopenic obesity (defined by VAT:FFMI) vs. Non-sarcopenic obesity was evaluated on Metabolic syndrome (OR 4.06, 95% CI 3.31-4.97, p=<0.001). Sarcopenic obesity, defined by the VAT:FFMI ratio, was significantly associated with an increased risk of metabolic syndrome (adjusted OR 4.06) in Northern Italian adults.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: